Scarica l'app Stockscreener
4.45
1.60%
0.07
Dopo l'orario di chiusura:
4.45
Precedente Chiudi:
$4.38
Aprire:
$4.44
Volume 24 ore:
193.22K
Relative Volume:
0.20
Capitalizzazione di mercato:
$153.01M
Reddito:
-
Utile/perdita netta:
$-86.60M
Rapporto P/E:
-1.5711
EPS:
-2.8324
Flusso di cassa netto:
$-67.37M
1 W Prestazione:
+6.46%
1M Prestazione:
+57.80%
6M Prestazione:
-38.96%
1 anno Prestazione:
-70.11%
Intervallo 1D:
$4.321
$4.50
Intervallo di 1 settimana:
$3.91
$4.50
Portata 52W:
$1.45
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Nome
Lexeo Therapeutics Inc
Settore
Industria
Telefono
(212) 547-9879
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK
Confronta LXEO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.45 | 153.01M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-06 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-28 | Iniziato | Chardan Capital Markets | Buy |
| 2023-11-28 | Iniziato | JP Morgan | Overweight |
| 2023-11-28 | Iniziato | Leerink Partners | Outperform |
| 2023-11-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-28 | Iniziato | Stifel | Buy |
Mostra tutto
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Bank of America Corp DE Trims Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics files to sell 41.63M shares of common stock for holders - MSN
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares - GuruFocus
Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders - MarketScreener
Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares | LXEO Stock News - GuruFocus
Jane Street Group LLC Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stake Lifted by Wellington Management Group LLP - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLC - Defense World
Deutsche Bank AG Buys 8,378 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Wilson Sonsini Advises Lexeo Therapeutics on $80 Million Private Placement Equity Financing - Wilson Sonsini
Lexeo Therapeutics (NASDAQ:LXEO) Given New $10.00 Price Target at JPMorgan Chase & Co. - Defense World
Leerink Partnrs Issues Optimistic Outlook for LXEO Earnings - Defense World
Lexeo Therapeutics (LXEO) Price Target Lowered by JP Morgan | LX - GuruFocus
Lexeo Therapeutics (LXEO) Price Target Lowered by JP Morgan | LXEO Stock News - GuruFocus
BNP Paribas Financial Markets Buys 28,986 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo raises $80 million to shore up gene therapy work after layoffs - The Pharma Letter
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook - Investing.com Australia
Leerink cuts Lexeo Therapeutics price target to $10, maintains outlook By Investing.com - Investing.com India
Lexeo Therapeutics raises $80M in private placement (LXEO) - Seeking Alpha
Lexeo Therapeutics secures $80 million in private placement By Investing.com - Investing.com South Africa
Lexeo Therapeutics (LXEO) Secures $80M from Private Placement | - GuruFocus
Lexeo Therapeutics Announces $80 Mln Private Placement Of Shares - Nasdaq
Lexeo Therapeutics Announces $80 Million Equity Financing - marketscreener.com
Lexeo prices 20.8M shares at $2.8825 in private placement - TipRanks
Lexeo Therapeutics Announces $80M Private Placement Agreement - TipRanks
Lexeo Therapeutics (LXEO) Secures $80M from Private Placement | LXEO Stock News - GuruFocus
Lexeo Therapeutics secures $80 million in private placement - Investing.com
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases - The Manila Times
Lexeo Therapeutics Secures $80 Million Financing to Extend Cash Runway into 2028 for Clinical Programs - Nasdaq
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of ... - Bluefield Daily Telegraph
Major Investors Back Lexeo Therapeutics with $80M for Breakthrough Genetic Heart Disease Programs - Stock Titan
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Rating of “Buy” by Brokerages - Defense World
Price T Rowe Associates Inc. MD Acquires New Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Q1 Earnings Forecast for LXEO Issued By HC Wainwright - Defense World
FY2025 Earnings Forecast for LXEO Issued By Chardan Capital - Defense World
HC Wainwright Lowers Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $15.00 - Defense World
Lexeo stock price target cut to $15 by H.C. Wainwright - Investing.com South Africa
Lexeo Therapeutics price target lowered to $15 from $23 at H.C. Wainwright - TipRanks
Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Superior Safety Profile Drive Buy Rating - TipRanks
#ASGCT25: In three patients, Rocket’s second heart gene therapy shows promise - Endpoints News
Lexeo Therapeutics (LXEO) Analyst Rating Update and Price Target Adjustment | LXEO Stock News - GuruFocus
Lexeo Therapeutics (LXEO) Price Target Cut to $15 by H.C. Wainwr - GuruFocus
Leerink Partnrs Has Bearish Forecast for LXEO Q2 Earnings - Defense World
Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price - Defense World
Lexeo Therapeutics: Strategic Focus and Promising Pipeline Drive Buy Rating - TipRanks
Lexeo Therapeutics (LXEO) Sees Price Target Adjustment by Charda - GuruFocus
Chardan Adjusts Price Target on Lexeo Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
Lexeo Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Lexeo Therapeutics price target lowered to $20 from $22 at Chardan - TipRanks
Lexeo Therapeutics Inc Azioni (LXEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexeo Therapeutics Inc Azioni (LXEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
May 16 '25 |
Sale |
2.77 |
585 |
1,623 |
67,681 |
| Robertson Jenny | Chief Legal Officer |
May 16 '25 |
Sale |
2.77 |
521 |
1,445 |
63,098 |
| See Tai Sandi | Chief Development Officer |
May 16 '25 |
Sale |
2.77 |
367 |
1,018 |
59,242 |
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):